Eterna Therapeutics Expects to Begin First-in-Human Ovarian Cancer Trial in H2
MT Newswires Live
Jan 06
Eterna Therapeutics (ERNA) said Tuesday it is on track to initiate its first-in-human ovarian cancer trial in H2 2026.
The company said it recently concluded a pre-investigational new drug application meeting with the US Food and Drug Administration, with feedback from the agency setting a pathway for submitting an investigational new drug application.
Eterna said that following the meeting, it has boosted key operational activities, with tech transfer already underway.
The company said it is currently progressing ERNA-101 therapy for ovarian cancer and ERNA-201 for autoimmune disease.
Ernexa Therapeutics shares were down 4% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.